arrow
K

Katherine R. Tuttle

university of washington school of medicine
H指数:92
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

使用司美格鲁肽治疗时,不同慢性肾病分期患者的代谢和血压结局变化:<scp>FLOW</scp>试验的事后分析

2026-11-030
OAAI
Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial

FLOW试验中根据慢性肾病严重程度划分的司美格鲁肽安全性结局

2026-10-200
OAAI
Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis

非糖尿病性高血压慢性肾脏病患者中的非奈利酮:FIND-CKD亚组分析

2026-08-300
OAAI
SGLT2 inhibition modulates metabolic; vascular; and inflammatory molecular markers in the kidney in youth with type 1 diabetes

SGLT2抑制剂调节1型糖尿病青少年肾脏中的代谢、血管和炎症分子标志物

2026-07-220
PRE
Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

维卡多司他/恩格列净对慢性肾脏病患者的影响:代谢亚组分析

2026-05-050
OAAI
A Scoping Review of Pharmacist-Based Interprofessional Interventions for Management of Cardiovascular-Kidney-Metabolic Conditions

基于药师的多专业协作干预措施在心血管-肾脏-代谢疾病管理中的范围综述

2026-03-110
PRE
Finerenone in Type 1 Diabetes and Chronic Kidney Disease

非奈利酮在1型糖尿病和慢性肾脏病中的应用

2026-03-0510
PRE
Case Series of Histopathological Findings in Chronic Kidney Disease: Insights From the Kidney Precision Medicine Project

慢性肾病病理学发现病例系列研究:来自肾脏精准医学项目的见解

2025-12-120
OAAI
REMODELing Mechanistic Trials for Kidney Disease: a multi-modal, tissue-centered approach to understand the renal mechanism of action of semaglutide

REMODELing机制试验用于肾脏疾病:一种多模态、组织中心化的方法,用于理解semaglutide的肾脏作用机制

2025-11-070
OAAI
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

恩格列净对EMPA-KIDNEY研究中尿液生物标志物的影响

2025-10-310
OAAI